Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 2/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | IDO1 | P14902 | 4/20 | 0.31 |
| ▸ | AGXT | P21549 | 2/20 | 0.31 |
| ▸ | APLNR | P35414 | 1/20 | 0.31 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.31 |
| ▸ | MMP2 | P08253 | 1/20 | 0.31 |
| ▸ | MMP13 | P45452 | 1/20 | 0.31 |
| ▸ | MMP14 | P50281 | 1/20 | 0.31 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30817963 | 1.00 | DUT (0.36) | DUTP2RX7CNR1CNR2IDO1 | |
| SCHEMBL31573468 | 0.92 | P2RX7 (0.34) | DUTP2RX7IDO1AGXTAPLNR | |
| SCHEMBL5378118 | 0.87 | ADAMTS4 (0.33) | P2RX7CNR1CNR2ADAMTS4MMP2 | |
| SCHEMBL17410221 | 0.83 | PYCR1 (0.36) | DUTIDO1 | |
| SCHEMBL29565283 | 0.80 | NR3C1 (0.34) | DUTNR3C1 | |
| SCHEMBL17979949 | 0.80 | NR3C1 (0.34) | DUTNR3C1 | |
| SCHEMBL30667522 | 0.80 | TAAR1 (0.41) | DUTIDO1 | |
| SCHEMBL9566221 | 0.80 | TAAR1 (0.41) | DUTIDO1 | |
| SCHEMBL13563967 | 0.78 | CYP11B1 (0.40) | DUTIDO1 | |
| SCHEMBL20220477 | 0.77 | SLC6A4 (0.36) | P2RX7IDO1AGXTAPLNRPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4046995-B1 | 1-HETEROCYCLYL ISOCHROMANYL COMPOUNDS AND ANALOGS FOR TREATING CNS DISORDERS | SUNOVION PHARMACEUTICALS INC (US) | 2023-09-13 | — | — | EP | disclosed |
| EP-4046995-B1 | 1-HETEROCYCLYL ISOCHROMANYL COMPOUNDS AND ANALOGS FOR TREATING CNS DISORDERS | SUNOVION PHARMACEUTICALS INC (US) | 2023-09-13 | — | — | EP | disclosed |
| EP-4046995-A1 | 1-HETEROCYCLYL ISOCHROMANYL COMPOUNDS AND ANALOGS FOR TREATING CNS DISORDERS | Sunovion Pharmaceuticals Inc. (US) | 2022-08-24 | — | — | EP | disclosed |
| EP-3256466-B9 | 1-HETEROCYCLYL ISOCHROMANYL COMPOUNDS AND ANALOGS FOR TREATING CNS DISORDERS | SUNOVION PHARMACEUTICALS INC (US) | 2022-07-27 | — | — | EP | disclosed |
| US-20220185799-A1 | 1-HETEROCYCLYL ISOCHROMANYL COMPOUNDS AND ANALOGS FOR TREATING CNS DISORDERS | SUNOVION PHARMACEUTICALS INC. (US) | 2022-06-16 | — | — | US | disclosed |
| EP-3256466-B1 | 1-HETEROCYCLYL ISOCHROMANYL COMPOUNDS AND ANALOGS FOR TREATING CNS DISORDERS | SUNOVION PHARMACEUTICALS INC (US) | 2022-04-06 | — | — | EP | disclosed |
| US-11192885-B2 | 1-heterocyclyl isochromanyl compounds and analogs for treating CNS disorders | SUNOVION PHARMACEUTICALS INC. (US) | 2021-12-07 | — | — | US | disclosed |
| US-10336732-B2 | 1-heterocyclyl isochromanyl compounds and analogs for treating CNS disorders | SUNOVION PHARMACEUTICALS INC. (US) | 2019-07-02 | — | — | US | disclosed |
| US-20180093974-A1 | 1-HETEROCYCLYL ISOCHROMANYL COMPOUNDS AND ANALOGS FOR TREATING CNS DISORDERS | SUNOVION PHARMACEUTICALS INC. (US) | 2018-04-05 | — | — | US | disclosed |
| US-20180093974-A1 | 1-HETEROCYCLYL ISOCHROMANYL COMPOUNDS AND ANALOGS FOR TREATING CNS DISORDERS | SUNOVION PHARMACEUTICALS INC. (US) | 2018-04-05 | — | — | US | disclosed |
| US-9856238-B2 | 1-heterocyclyl isochromanyl compounds and analogs for treating CNS disorders | SUNOVION PHARMACEUTICALS INC. (US) | 2018-01-02 | — | — | US | disclosed |
| US-9856238-B2 | 1-heterocyclyl isochromanyl compounds and analogs for treating CNS disorders | SUNOVION PHARMACEUTICALS INC. (US) | 2018-01-02 | — | — | US | disclosed |
| EP-3256466-A1 | 1-HETEROCYCLYL ISOCHROMANYL COMPOUNDS AND ANALOGS FOR TREATING CNS DISORDERS | Sunovion Pharmaceuticals Inc. (US) | 2017-12-20 | — | — | EP | disclosed |
| US-20170001987-A1 | 1-HETEROCYCLYL ISOCHROMANYL COMPOUNDS AND ANALOGS FOR TREATING CNS DISORDERS | SUMITOMO PHARMA AMERICA, INC. | 2017-01-05 | — | — | US | disclosed |
| US-20170001987-A1 | 1-HETEROCYCLYL ISOCHROMANYL COMPOUNDS AND ANALOGS FOR TREATING CNS DISORDERS | SUMITOMO PHARMA AMERICA, INC. | 2017-01-05 | — | — | US | disclosed |
| US-20170001987-A1 | 1-HETEROCYCLYL ISOCHROMANYL COMPOUNDS AND ANALOGS FOR TREATING CNS DISORDERS | SUMITOMO PHARMA AMERICA, INC. | 2017-01-05 | — | — | US | disclosed |
| WO-2016130796-A1 | 1-HETEROCYCLYL ISOCHROMANYL COMPOUNDS AND ANALOGS FOR TREATING CNS DISORDERS | SUNOVION PHARMACEUTICALS INC. (US) | 2016-08-18 | — | — | WO | disclosed |
| WO-2016130796-A1 | 1-HETEROCYCLYL ISOCHROMANYL COMPOUNDS AND ANALOGS FOR TREATING CNS DISORDERS | SUNOVION PHARMACEUTICALS INC. (US) | 2016-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170001987-A1 | 1-HETEROCYCLYL ISOCHROMANYL COMPOUNDS AND ANALOGS FOR TREATING CNS DISORDERS | CNR1, HCRTR1, CNR2 | DUT 4551/4885P2RX7 2110/4885CNR1 1/4885 |
| US-11192885-B2 | 1-heterocyclyl isochromanyl compounds and analogs for treating CNS disorders | CNR1, HCRTR1, CNR2 | DUT 4551/4885P2RX7 2110/4885CNR1 1/4885 |
| US-20180093974-A1 | 1-HETEROCYCLYL ISOCHROMANYL COMPOUNDS AND ANALOGS FOR TREATING CNS DISORDERS | CNR1, HCRTR1, CNR2 | DUT 4551/4885P2RX7 2110/4885CNR1 1/4885 |
| US-20220185799-A1 | 1-HETEROCYCLYL ISOCHROMANYL COMPOUNDS AND ANALOGS FOR TREATING CNS DISORDERS | CNR1, HCRTR1, CNR2 | DUT 4551/4885P2RX7 2110/4885CNR1 1/4885 |
| US-10336732-B2 | 1-heterocyclyl isochromanyl compounds and analogs for treating CNS disorders | CNR1, HCRTR1, CNR2 | DUT 4551/4885P2RX7 2110/4885CNR1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.